MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mltx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) measures how much investors pay for each dollar of the company's trailing earnings. MLTX's current PE ratio of N/A is calculated by dividing its stock price of $18.00 by its TTM earnings per share of -$3.61.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2020 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
MoonLake ImmunotherapeuticsYou MLTX | $1.3B | N/A | — | -$3.61 |
 Absci Corporation ABSI | $1.0B | N/A | — | -$0.84 |
 ArriVent BioPharma, Inc. Common Stock AVBP | $1.4B | N/A | — | -$4.32 |
 CytomX Therapeutics, Inc. CTMX | $473M | N/A | — | -$0.13 |
 Erasca, Inc. ERAS | $4.0B | N/A | — | -$0.44 |
 MBX Biosciences, Inc. Common Stock MBX | $974M | N/A | — | -$2.38 |
 MeiraGTx Holdings plc MGTX | $842M | N/A | — | -$1.42 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.53 | — | |
2024-12-31 FY2024 | — | $-1.89 | — | |
2023-12-31 FY2023 | — | $-0.73 | — | |
2022-12-31 FY2022 | — | $-1.70 | — | |
2021-12-31 FY2021 | — | $-1.45 | — | |
2020-12-31 FY2020 | — | $-0.01 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) measures how much investors pay for each dollar of the company's trailing earnings. MLTX's current PE ratio of N/A is calculated by dividing its stock price of $18.00 by its TTM earnings per share of -$3.61.
Frequently asked questions
MLTX pe ratio · 6 questionsMLTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $18.00 and TTM EPS of -$3.61. Data sourced from Financial Modeling Prep via MLTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MoonLake Immunotherapeutics SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08